- Home
- CNTA vs GPCR Comparison
CNTA vs GPCR Comparison
Compare CNTA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- GPCR
- Stock Information
- Founded
- CNTA 2020
- GPCR 2016
- Country
- CNTA United Kingdom
- GPCR United States
- Employees
- CNTA N/A
- GPCR N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- GPCR
- Sector
- CNTA Health Care
- GPCR
- Exchange
- CNTA Nasdaq
- GPCR Nasdaq
- Market Cap
- CNTA 1.6B
- GPCR 1.1B
- IPO Year
- CNTA 2021
- GPCR 2023
- Fundamental
- Price
- CNTA $14.07
- GPCR $20.79
- Analyst Decision
- CNTA Strong Buy
- GPCR Strong Buy
- Analyst Count
- CNTA 10
- GPCR 7
- Target Price
- CNTA $28.78
- GPCR $76.17
- AVG Volume (30 Days)
- CNTA 1.2M
- GPCR 761.9K
- Earning Date
- CNTA 08-12-2025
- GPCR 08-07-2025
- Dividend Yield
- CNTA N/A
- GPCR N/A
- EPS Growth
- CNTA N/A
- GPCR N/A
- EPS
- CNTA N/A
- GPCR N/A
- Revenue
- CNTA $15,000,000.00
- GPCR N/A
- Revenue This Year
- CNTA N/A
- GPCR N/A
- Revenue Next Year
- CNTA N/A
- GPCR N/A
- P/E Ratio
- CNTA N/A
- GPCR N/A
- Revenue Growth
- CNTA 118.88
- GPCR N/A
- 52 Week Low
- CNTA $8.46
- GPCR $13.22
- 52 Week High
- CNTA $19.09
- GPCR $47.48
- Technical
- Relative Strength Index (RSI)
- CNTA 60.47
- GPCR 38.49
- Support Level
- CNTA $12.74
- GPCR $20.70
- Resistance Level
- CNTA $14.27
- GPCR $23.67
- Average True Range (ATR)
- CNTA 0.66
- GPCR 1.24
- MACD
- CNTA 0.12
- GPCR -0.08
- Stochastic Oscillator
- CNTA 85.57
- GPCR 13.93
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.